Infections: The Overlooked Epidemic Driving Diabetes Mortality and Costs

The City St George's observational cohort study (linked GP-hospital-mortality records, n>800k diabetes/prediabetes cases vs 1M+ matched controls, 5-year follow-up) reveals infection as the third-leading cause of death in type 2 diabetes, with 337% elevated hospitalization risk in type 1. This large-scale analysis (observational, no RCT) underscores blood-glucose variability as a stronger predictor than mean HbA1c for severe events in type 2, a nuance often missed in prior smaller studies. Yet it underplays socioeconomic confounders and vaccination gaps that amplify risks, as shown in a 2022 CDC-linked analysis (Diabetes Care, n=1.2M US adults) tying low pneumococcal uptake to 22% excess sepsis deaths. Synthesizing with a 2021 Lancet Diabetes & Endocrinology review on immune dysregulation, these patterns connect directly to surging chronic-disease burdens: infection-driven admissions now rival cardiovascular events in cost, per UK NHS data, yet guidelines omit routine infection metrics. Conflicts of interest were unreported in the primary study, but its England-only scope limits global generalizability. Embedding infection prevention—prioritized triage, variability monitoring, and early antibiotics—could cut hospitalizations 20-30% while addressing the systemic under-recognition that inflates healthcare expenditures amid rising prediabetes prevalence.